Florey Institute of Neuroscience & Mental Health

What Florey Institute of Neuroscience & Mental Health does

The Florey Institute of Neuroscience & Mental Health is one of Australia's largest dedicated neuroscience and mental health research institutes, founded in 1971 and headquartered in Parkville, Melbourne. It employs 501-1000 staff and conducts research across five priority areas: Dementia, Epilepsy and Neurodevelopment, Mental Health, Neurodegeneration and Immunology, and Stroke and Critical Care. The institute operates a substantial scientific infrastructure footprint, including Advanced Microscopy, MRI with MRI-guided focused ultrasound (MRgFUS), the National Dementia Diagnostics Laboratory, the Australian National CJD Registry, the Victorian Brain Bank, BioAnalytics Australia, Behaviour Facility, Bioresources, CREDOS-Biotech, Neurohistology Laboratory, Neuroscience Trials Australia, and NeuroStem. It also runs the Melbourne Neuroscience PhD Program, postdoc and student associations, and a formal commercialisation arm.

The Florey's business model is grant-funded research, supplemented by industry collaborations, clinical trials, philanthropic donations, and translational commercialisation. In November 2025 it entered a strategic research collaboration with South Korean AI firm Neurophet to clinically evaluate Neurophet AQUA, an AI-driven brain neurodegeneration imaging software, for biomarker-based Alzheimer's disease diagnosis under the joint 'Enhanced Dementia Diagnosis (EDD)' study. This positions the Florey as a clinical validator of third-party AI imaging tools rather than as an AI developer. Funding sources include Australian federal vehicles such as the Medical Research Future Fund (a $1,000,000 MRFF grant is disclosed in June 2019), alongside institutional, university-affiliated, and philanthropic support.

Revenue mechanics are not publicly disclosed: pricing is not listed, and the institute does not sell products commercially. Its operations are sustained through competitive research grants, contracted research collaborations, clinical trial activity via Neuroscience Trials Australia, and a publicly visible donation channel. There are no disclosed funding rounds, acquisitions, investments, patents, trademarks, awards, or customer logos in the input data, and no management team or board beyond COO Peter Plecher and Laboratory Head Thomas Oxley is named, leaving ownership, cap table, and full leadership structure as data gaps.

Name

Florey Institute of Neuroscience & Mental Health

Legal name

Florey Institute of Neuroscience & Mental Health

Website

https://florey.edu.au

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The Florey Institute of Neuroscience & Mental Health, founded in 1971 and based in Melbourne, Australia, is a non-commercial neuroscience and mental health research institute employing 501-1000 staff across five research priority areas, operating extensive scientific facilities and grant-funded research collaborations including AI imaging validation for Alzheimer's diagnosis.

Ownership category

akta.pro rank

Product category

Neuroscience Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Social Sciences and Humanities (541720)

SIC

Services-Engineering, Accounting, Research, Management (8700)

akta.pro primary industry

Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

akta.pro secondary industries

Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Epilepsy & Seizure Disorders (HLAKAIAB), Neurodiagnostic Centers (EEG/EMG/NCS) (HLAFAKAK)

Keywords

• Neuroscience research
• Mental health research
• Dementia diagnostics
• Brain imaging services
• Clinical neuroscience trials

Headquarters

HQ city

Parkville

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. Research collaboration and grant-funded partnerships: As a neuroscience research institute, The Florey engages in joint research collaborations with industry partners such as Neurophet to evaluate AI imaging tools for dementia diagnosis. Revenue is generated through research partnerships, grants, and institutional funding.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

The Florey Institute of Neuroscience & Mental Health is a Melbourne-based neuroscience and mental health research institute that conducts fundamental and clinical research across five priority areas: Dementia, Epilepsy and Neurodevelopment, Mental Health, Neurodegeneration and Immunology, and Stroke and Critical Care. It delivers scientific facilities and research services (advanced microscopy, MRI, neurohistology, brain banking, bioanalytics, clinical trials) and partners with industry to clinically validate tools such as Neurophet AQUA for Alzheimer's diagnosis.

Product overview

Florey Institute of Neuroscience & Mental Health is undertaking an AI-powered imaging research program focused on Alzheimer's disease diagnosis, structured around a single flagship joint study — the 'Enhanced Dementia Diagnosis (EDD)' collaboration with Neurophet. This research initiative evaluates Neurophet's AQUA AI-driven brain neurodegeneration imaging software to improve high-precision dementia diagnosis in clinical settings, leveraging AI to analyze brain imaging biomarkers.

Differentiator

Problem solved

Functional benefit

Products and services

• Magnetic resonance imaging (MRI) services
• Advanced Microscopy services
• Neurohistology Laboratory services
• BioAnalytics Australia
• Bioresources
• Behaviour Facility
• Victorian Brain Bank
• National Dementia Diagnostics Laboratory
• Australian National CJD Registry
• Neuroscience Trials Australia
• NeuroStem
• CREDOS-Biotech
• Enhanced Dementia Diagnosis (EDD) joint study with Neurophet

Quantifiable outcome

• Improved high-precision dementia diagnosis in clinical settings via AI-powered imaging

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• NeurophetcoreStrategic or Co-development Partner · 4 December 2025The Florey Institute in Melbourne has begun a partnership with South Korean firm Neurophet to evaluate AI-powered imaging for Alzheimer's disease diagnosis. The collaboration centers on clinical evaluation of Neurophet's AI imaging tools for Alzheimer's disease diagnosis.
• NeurophetcoreStrategic or Co-development Partner · 25 November 2025The Florey Institute and Neurophet announced a strengthened research collaboration to evaluate biomarkers for Alzheimer's disease diagnosis using Neurophet's AI-driven brain neurodegeneration imaging software, Neurophet AQUA. The joint study, titled 'Enhanced Dementia Diagnosis (EDD)', aims to improve high-precision dementia diagnosis in clinical settings by leveraging Neurophet's AI technology and The Florey's neuroscience research expertise.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• QIMR Berghofer Medical Research Institute: Major Australian medical research institute headquartered in Brisbane. Comparable as a fellow large-scale Australian translational research body with similar grant-funded model, commercial arm, and disease-priority research structure.
• Max Planck Institute for Neuroscience: Germany-based neuroscience research institute within the Max Planck Society. Comparable to Florey in dedicated neuroscience research focus, advanced imaging infrastructure, and international publication footprint.
• Walter and Eliza Hall Institute of Medical Research (WEHI): Australia's largest medical research institute, also based in Melbourne's Parkville precinct. Highly comparable to Florey as a peer Australian medical research organization of similar scale, with overlapping immunology, neuroscience, and commercial-translation capabilities.
• Allen Institute for Brain Science: US-based nonprofit neuroscience research institute focused on brain mapping, neurodegeneration, and large-scale data resources. Directly comparable to Florey in mission (open neuroscience research) and in leveraging advanced imaging and computation to study brain disease.
• Neuroscience Research Australia (NeuRA): Sydney-based independent neuroscience research institute. Highly comparable to Florey as a fellow Australian neuroscience research body, with overlapping focus on dementia, neurodegeneration, and brain injury research.

Broad incumbents

• Howard Hughes Medical Institute (HHMI): One of the world's largest biomedical research organizations. Comparable as a much larger, established research-funding and operating institute with overlapping neuroscience and imaging research, but operates at vastly greater scale and broader scope than Florey.
• Karolinska Institutet (Department of Neuroscience): Sweden's premier medical university with major neuroscience research programs. Comparable to Florey in translational neuroscience and dementia research, but operates as a much larger, broader academic institution.

Regional players

• South Australian Health and Medical Research Institute (SAHMRI): Adelaide-based Australian health and medical research institute of similar scale and funding model. Comparable to Florey as a domestic Australian peer but serves a different state/region and does not specialize in neuroscience.

Emerging players

• icometrix: Commercial AI brain imaging vendor (icobrain) for multiple sclerosis, dementia, and traumatic brain injury. Comparable to Florey's Neurophet partnership as a commercial AI neuroimaging peer, though focused on a broader set of indications and operating commercially rather than as a research institute.
• Cortechs.ai: US-based AI medical imaging company specializing in quantitative MRI biomarkers for neurodegenerative disease. Comparable as a commercial peer in AI-driven brain imaging for Alzheimer's and related dementias — directly adjacent to the work Florey is validating with Neurophet.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/theflorey
• Facebookfacebook.com/theflorey
• LinkedInlinkedin.com/company/florey-neuroscience-institutes

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Florey Institute of Neuroscience & Mental Health